Tranexamic%252525252525252525252525252520acid

# Tranexamic Acid (TXA) ## Overview Tranexamic acid is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots. It is available as oral tablets and intravenous (IV) solution. ## Primary Indications * **Trauma:** Management of hemorrhage in severely injured patients. * **Surgery:** Prevention/reduction of perioperative blood loss (e.g., cardiac, orthopedic). * **Menorrhagia:** Treatment of cyclic heavy menstrual bleeding. * **Hemorrhage:** Management of epistaxis, dental bleeding in hemophiliacs, and postpartum hemorrhage (off-label). ## Adult Dosing * **Trauma:** 1 g IV bolus over 10 minutes, followed by 1 g infusion over 8 hours. Administer as soon as possible, ideally within 3 hours of injury. * **Menorrhagia:** 1.3 g orally three times daily for up to 5 days during menstruation. * **Surgery:** Dosing varies widely by protocol; common regimens include 10–20 mg/kg IV bolus followed by 1–10 mg/kg/hour infusion. ## Pediatric Dosing * **Trauma (Off-label):** 15–20 mg/kg IV bolus (max 1 g), followed by 2 mg/kg/hour infusion. * **General Hemostasis:** 10–25 mg/kg IV every 6–8 hours. * *Note: Always verify institutional guidelines for pediatric trauma protocols as they may differ.* ## Dose Adjustments * **Renal Impairment:** Reduce dosing in patients with impaired renal function (creatinine clearance < 50 mL/min) to avoid accumulation. For dialysis patients, dosing requires specialist consultation. * **Hepatic Impairment:** No specific adjustment required; use with caution. ## Contraindications * History of venous or arterial thrombosis (e.g., DVT, pulmonary embolism). * Active intravascular clotting. * Subarachnoid hemorrhage (due to risk of cerebral ischemia). * Hypersensitivity to TXA. * Color vision disturbances (acquired). ## Adverse Effects * **Gastrointestinal:** Nausea, vomiting, diarrhea, abdominal pain (frequent with oral dosing). * **Neurological:** Seizures (often dose-dependent or associated with high-dose cardiac surgery). * **Vascular:** Thromboembolic events, hypotension (if IV push is too rapid). * **Ocular:** Visual disturbances (rare). ## Key Drug Interactions * **Thrombolytics/Fibrinolytics (e.g., tPA):** Antidote-like effect; avoid concurrent use. * **Estrogens/Combined Oral Contraceptives:** May increase the risk of thrombosis when used with TXA. * **Factor IX complex/Prothrombin complex concentrates:** Increased risk of thrombosis. ## Monitoring * **Clinical:** Assess for signs of DVT/PE (swelling, chest pain, dyspnea). * **Neurological:** Monitor for seizure activity, particularly during high-dose rapid infusion. * **Renal:** Monitor serum creatinine in patients with baseline renal impairment. ## Clinical Pearls * **Administration:** IV bolus administration should be slow (over 10+ minutes) to prevent hypotension. * **CRASH-2/WISH trials:** Demonstrated mortality benefit in trauma patients when administered within 3 hours; benefit diminishes or disappears after 3 hours. * **Visual disturbance:** If vision changes occur, discontinue medication immediately and perform an ophthalmologic exam. *** **Educational Disclaimer:** This information is for educational purposes and is not a substitute for clinical judgment. Always verify current prescribing information, institutional protocols, and dose calculations with the latest official drug monographs (e.g., Lexicomp, UpToDate) before administering medication.